Price Targets For Sobi

Stockholm Stock Exchange | Large Cap

Sobi

+10.05%

Pareto SecuritiesBarclaysExane BNP ParibasBerenbergDeutsche BankDNB CarnegieNordeaRBCSEBJefferiesSEB EquitiesDNB MarketsKepler CheuvreuxNordea MarketsCarnegieMorgan StanleyHSBCRBC Capital MarketsDNBHandelsbanken Capital MarketsMorningstarDanske Bank MarketsDanske BankJefferies InternationalHandelsbankenABG Sundal Collier

Latest Price Target For Sobi

Upside:

+10.05%

Analyst	Price Target	Date
Pareto Securities	460 SEK	Apr 16

Price Targets Last 3 Months For Sobi

Upside:

+10.05%

Analyst	Price Target	Date
Pareto Securities	460 SEK	Apr 16

All Price Targets For Sobi

Analyst	Price Target	Date
Pareto Securities	460 SEK	Apr 16
Barclays	395 SEK	Jan 8
Exane BNP Paribas	320 SEK	Dec -25
Berenberg	405 SEK	Nov -25
Deutsche Bank	370 SEK	Nov -25
DNB Carnegie	400 SEK	Oct -25
Nordea	372 SEK	Oct -25
RBC	405 SEK	Jan -25
SEB	400 SEK	Oct -24
Jefferies	310 SEK	Oct -24
SEB Equities	300 SEK	Oct -24
DNB Markets	335 SEK	Sep -24
Kepler Cheuvreux	330 SEK	Sep -24
Nordea Markets	340 SEK	Jul -24
Carnegie	330 SEK	Apr -24
Morgan Stanley	325 SEK	Feb -24
HSBC	330 SEK	Feb -24
RBC Capital Markets	325 SEK	Nov -23
DNB	300 SEK	Oct -23
Handelsbanken Capital Markets	335 SEK	Sep -23
Morningstar	252 SEK	Jul -23
Danske Bank Markets	325 SEK	Apr -23
Danske Bank	275 SEK	Oct -22
Jefferies International	295 SEK	Sep -22
Handelsbanken	197 SEK	Jul -21
ABG Sundal Collier	162 SEK	Feb -21

About The Company

Swedish Orphan Biovitrum (Sobi) is a pharmaceutical company with two focus areas: haemophilia and rare diseases. Sobi is a merger of Swedish Orphan and Biovitrum. The company has its premises in Karolinska Institutet Science Park in Solna.
Wikipedia